0000000000102056

AUTHOR

Mohamed Abuzakouk

showing 2 related works from this author

The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria

2022

This update and revision of the international guideline for urticaria was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the Global Allergy and Asthma European Network (GALEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), the European Dermatology Forum (EDF; EuroGuiDerm), and the Asia Pacific Association of Allergy, Asthma and Clinical Immunology with the participation of 64 delegates of 50 national and international soci…

medicine.medical_specialtyEvidence-based practicehivesmedia_common.quotation_subjectImmunologyeducation610DermatologyAngioedema/diagnosis030207 dermatology & venereal diseases03 medical and health sciencesurticaria0302 clinical medicineQuality of lifeExcellenceimmune system diseasesevidence-basedparasitic diseasesmedicinePrevalenceImmunology and Allergymedia_common.cataloged_instanceHumansitchEuropean unionskin and connective tissue diseaseswhealAsthmamedia_commonAngioedemabusiness.industryangioedemaConsensus conferenceGUIDELINES ; angioedema ; consensus ; evidence2̆010based ; hives ; itch ; mast cell ; urticaria ; whealGuidelinemedicine.diseaseAsthma3. Good healthddc:030228 respiratory systemconsensusFamily medicineChronic DiseaseQuality of LifeUrticaria/diagnosismedicine.symptombusinessmast cell600 Technik Medizin angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
researchProduct

The global impact of the COVID-19 pandemic on the management and course of chronic urticaria

2021

Introduction: the COVID-19 pandemic dramatically disrupts health care around the globe. The impact of the pandemic on chronic urticaria (CU) and its management are largely unknown. Aim: to understand how CU patients are affected by the COVID-19 pandemic; how specialists alter CU patient management; and the course of CU in patients with COVID-19. Materials and methods: our cross-sectional, international, questionnaire-based, multicenter UCARE COVID-CU study assessed the impact of the pandemic on patient consultations, remote treatment, changes in medications, and clinical consequences. Results: the COVID-19 pandemic severely impairs CU patient care, with less than 50% of the weekly numbers o…

Male0301 basic medicineSTRESSExacerbationUCAREpandemijeMedizinOmalizumabOmalizumabSERUMchronic urticaria0302 clinical medicinePandemicHealth careImmunology and AllergyChronic UrticariatreatmentChronic urticaria; COVID-19; Cyclosporine; Omalizumab; Pandemic; SARS-CoV-2; Treatment; UCAREzdravljenjeASSOCIATIONMiddle AgedCOVID-19; SARS-CoV-2; UCARE; chronic urticaria; cyclosporine; omalizumab; pandemic; treatmentkronična urtikarijaINFECTIONSGA(2)LENCyclosporineFemale600 Technik Medizin angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheitmedicine.drugAdultmedicine.medical_specialtyAdolescentCoronavirus disease 2019 (COVID-19)Immunology610udc:616-097pandemicsciklosporinYoung Adult03 medical and health sciencesPatient referralmedicineHumansIn patientPatient Reported Outcome MeasurescyclosporineChronic urticariaAgedInternetPandemicSARS-CoV-2business.industrypandemicCOVID-19TreatmentDEFINITIONMedicine; Allergy; ImmunologyCross-Sectional Studies030104 developmental biology030228 respiratory systemEmergency medicineomalizumabbusinessAllergy: European Journal of Allergy and Clinical Immunology
researchProduct